VINEET LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.78 INR | +4.81% |
|
-5.51% | -29.03% |
| 05-30 | Vineet Laboratories CEO Resigns | MT |
| 05-29 | Vineet Laboratories Limited Announces Resignation of Satish Pandurang Samant as Executive Director | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.91K 159K 150K | Sales 2023 | 2.12K 176K 167K | Capitalization | 382M 31.71B 29.97B |
|---|---|---|---|---|---|
| Net income 2022 | 66M 5.48B 5.18B | Net income 2023 | 12M 997M 942M | EV / Sales 2022 | 273,707 x |
| Net Debt 2022 | 83.97M 6.98B 6.59B | Net Debt 2023 | 305M 25.31B 23.92B | EV / Sales 2023 | 323,255 x |
| P/E ratio 2022 |
6.62
x | P/E ratio 2023 |
30.5
x | Employees | 72 |
| Yield 2022 |
2.1% | Yield 2023 |
-
| Free-Float | 49.77% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.81% | ||
| 1 week | -5.51% | ||
| Current month | +4.81% | ||
| 1 month | +3.83% | ||
| 3 months | +2.74% | ||
| 6 months | -17.08% | ||
| Current year | -29.03% |
1 week
52.00
64.25
1 month
50.0364.25
Current year
46.9885.00
1 year
46.1088.95
3 years
38.20124.70
5 years
38.20124.70
10 years
38.20124.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 74 | 09/11/16 | |
| Compliance Officer | - | 11-09 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 09/11/16 | |
| Director of Finance/CFO | 74 | 09/11/16 | |
| Director/Board Member | 50 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/06/24 | 57.78 | +4.81% | 10 080 |
| 31/05/24 | 55.13 | -1.64% | 2,513 |
| 30/05/24 | 56.05 | -4.71% | 9,134 |
| 29/05/24 | 58.82 | +4.55% | 32,777 |
| 28/05/24 | 56.26 | -8.00% | 8,660 |
Delayed Quote Bombay S.E., June 03, 2024 at 11:00 am
More quotes
Vineet Laboratories Limited is engaged in the business of drug intermediates and bulk drugs. The Company specializes in pharmaceutical intermediates and fine chemicals. Its active pharmaceutical ingredient (API) intermediates include Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine. Its fine chemicals and reagents include Isopropyl-beta-D-thiogalactopyranoside, 4-Nitrophenyl phosphate disodium salt, 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal), 5-Acetyl thiophene-2-carboxilic acid, n-Butyl Lithium, n-Butyl magnesium chloride, 3-Furaldehyde, 3-bromofuran, 1-methyl-imidazole-2-carboxaldehyde, 6-Aminouracil, Ethyldiazo acetate, and Phenylboronic acid. It also exports API intermediates, fine chemicals, and custom synthesis molecules.
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +40.73% | 739B | |
| +31.77% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.42% | 240B | |
| +9.45% | 210B | |
| -5.44% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- VINEETLAB Stock
- VINEETLAB Stock
